Anti-CS3 IgG Avidity in Zambian Children Vaccinated with ETVAX

Avidity indices for anti-CS3 and anti-LTB IgG antibodies measured in 60 Zambian children aged 6–23 months. The data were collected as part of a study assessing the ETVAX® vaccine's immunogenicity in an endemic setting. Plasma samples were analyzed at baseline and after multiple vaccine doses using limiting antigen dilution ELISA.

Use Cases

• Compare antibody avidity against titre-defined naïve status based on the described classification thresholds.
• Analyze the relationship between antibody titres and avidity indices over time for CS3 and LTB antigens.
• Evaluate the discriminatory performance of avidity indices using ROC analysis metrics like AUC.
• Investigate inter-individual variability in vaccine-induced antibody responses in an endemic population.

Strengths

• Includes data from 60 pediatric participants, providing a cohort for analysis.
• Measures were taken at three time points (baseline, Day 22, Day 97), allowing for longitudinal assessment.
• Dataset is licensed under CC-BY-4.0, permitting open reuse with attribution.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small at 11.4 KB, indicating limited scope.

Provenance

Source

Cynthia Mubanga via figshare

Collection Method

Plasma samples from a clinical trial were analyzed by limiting antigen dilution ELISA.

Time Range

Samples collected on study days 1, 22, and 97.

Freshness

Last updated 2026-05-15 17:25:30; freshness should be verified.

Geography

Zambia